ESIGF yields 1.20% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, ESIGF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESIGF + PFE for your $10,000?
ESI Group SA, together with its subsidiaries, designs, develops, and distributes virtual prototyping software solutions in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. The company offers vibro-acoustics, which allows engineers to perform accurate predictive noise and vibration design assessments early in the design cycle; virtual reality and performance solutions; and virtual seat solutions. It also provides SimulationX, a single platform for modeling, simulating, and analyzing technical systems; SYSWELD, which enables the designers and process planners to virtually manufacture, assemble, and test physically realistic virtual assemblies; SYSTUS, which offers a complete resolution to analysis challenges in mechanics, heat transfer, and electrotechnics; PROSIVIC simulation software; PAM-STAMP that provides sheet metal forming solutions; interior solutions; PAM-COMPOSITES; ACE+ Suite, a CFD and high-fidelity multiphysics simulation software; and ProCAST, which offers casting solutions. In addition, the company offers consulting, technical support and assistance, and training services, as well as operates myESI, a customer portal. It serves aeronautics/aerospace, defense, naval, automotive, energy, ground transportation, heavy machinery, and other industries. The company was founded in 1973 and is headquartered in Rungis, France.
Full ESIGF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.